DeepMed Research

OBI PHARMA, INC.

🇨🇳China

Country: 🇨🇳China

Ownership: Public, Private

Established: 2002-01-01

Employees: -

Market Cap: -

Website: http://www.obi.fr

Clinical Trials

A Phase 1/2 Study of OBI-992 in Subjects With Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: OBI-992

First Posted Date: 2024-06-28

Last Posted Date: 2025-05-04

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 117

Registration Number: NCT06480240

Locations: 🇺🇸
California Clinical Trials Medical Group (CCTMG), Glendale, California, United States
🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States

and more 5 locations

To Evaluate OBI-833/OBI-821 in Combination With First-Line Erlotinib in Patients With EGFR-Mutated, Globo H-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Erlotinib (150 mg daily)
Biological: 30 μg OBI-833/100 μg OBI-821

First Posted Date: 2022-07-01

Last Posted Date: 2023-08-07

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 60

Registration Number: NCT05442060

Locations: 🇨🇳
National Taiwan University Cancer Center, Taipei, Da'an Dist., Taiwan
🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
🇨🇳
Tri-Service General Hospital, Taipei, Neihu District, Taiwan

and more 4 locations

Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Locally Advanced Solid Tumor

Interventions: Drug: OBI-999

First Posted Date: 2019-09-10

Last Posted Date: 2025-03-26

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 44

Registration Number: NCT04084366

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Scripps MD Anderson Cancer Center, La Jolla, California, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors

Phase 1

Terminated

Conditions: Solid Tumor
Pancreatic Adenocarcinoma

Interventions: Drug: OBI-3424

First Posted Date: 2018-07-19

Last Posted Date: 2024-10-15

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 68

Registration Number: NCT03592264

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 2 locations

This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.

Phase 1

Terminated

Conditions: Metastatic Solid Tumors
Locally Advanced Solid Tumors

Interventions: Drug: OBI-888
Device: Globo H IHC Assay

First Posted Date: 2018-06-29

Last Posted Date: 2024-02-22

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 54

Registration Number: NCT03573544

Locations: 🇺🇸
Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
🇺🇸
Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States

and more 6 locations

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Biological: adagloxad simolenin combined with OBI-821
Device: Globo H IHC Assay
Other: Standard of care treatment

First Posted Date: 2018-06-19

Last Posted Date: 2025-05-09

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 575

Registration Number: NCT03562637

Locations: 🇺🇦
CI Reg. Oncol. Dispanser, Zhytomyr, Ukraine
🇺🇸
Moores UCSD Cancer Center, La Jolla, California, United States
🇺🇸
Kaiser Permanente Medical Center, San Diego, California, United States

and more 125 locations

Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal or Breast Cancer Subjects

Phase 1

Completed

Conditions: Metastatic Gastric Cancer
Metastatic Breast Cancer
Metastatic Colorectal Cancer
Metastatic Lung Cancer

Interventions: Drug: OBI-833/OBI-821

First Posted Date: 2014-12-08

Last Posted Date: 2022-10-03

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 25

Registration Number: NCT02310464

Locations: 🇨🇳
Tri-Service General Hospital, Taipei, Taiwan
🇨🇳
Taipei Medical University Shuang Ho Hospital, New Taipei City, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan

and more 1 locations

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Biological: Phosphate Buffer Saline (PBS)
Biological: OPT-822/OPT-821(30 μg/100 μg)
Drug: Cyclophosphamide

First Posted Date: 2012-01-24

Last Posted Date: 2020-09-16

Lead Sponsor: OBI Pharma, Inc

Target Recruit Count: 349

Registration Number: NCT01516307

Locations: 🇮🇳
HCG, Bangalore Institute of Oncology, Bengaluru, India
🇮🇳
Curie Manavata Cancer Centre, Mumbai, India
🇺🇸
Memorial Regional Hospital, Hollywood, Florida, United States

and more 40 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy